59 related articles for article (PubMed ID: 20796207)
1. Epidemiology of thrombocytopenia in patients with chronic hepatitis C: more than meets the eye.
Giannini EG; Savarino V
J Viral Hepat; 2011 Jan; 18(1):8-10. PubMed ID: 20796207
[TBL] [Abstract][Full Text] [Related]
2. Thrombocytopenia in patients with HCV-positive chronic hepatitis: efficacy of leucocyte interferon-alpha treatment.
Benci A; Caremani M; Tacconi D
Int J Clin Pract; 2003; 57(1):17-9. PubMed ID: 12587936
[TBL] [Abstract][Full Text] [Related]
3. Medical resource utilisation and healthcare costs in patients with chronic hepatitis C viral infection and thrombocytopenia.
Poordad F; Theodore D; Sullivan J; Grotzinger K
J Med Econ; 2011; 14(2):194-206. PubMed ID: 21348807
[TBL] [Abstract][Full Text] [Related]
4. Predictors of hematological abnormalities in patients with chronic hepatitis C treated with interferon and ribavirin.
Nachnani JS; Rao GA; Bulchandani D; Pandya PK; Alba LM
Ann Hematol; 2010 Feb; 89(2):121-5. PubMed ID: 19565241
[TBL] [Abstract][Full Text] [Related]
5. Life-threatening severe immune thrombocytopenia during alpha-interferon therapy for chronic hepatitis C.
Fujii H; Kitada T; Yamada T; Sakaguchi H; Seki S; Hino M
Hepatogastroenterology; 2003; 50(51):841-2. PubMed ID: 12828100
[TBL] [Abstract][Full Text] [Related]
6. Severity of liver disease predicts the development of glucose abnormalities in patients with chronic hepatitis B or C following achievement of sustained virological response to antiviral therapy.
Chehadeh W; Al-Nakib W
J Med Virol; 2009 Apr; 81(4):610-8. PubMed ID: 19235842
[TBL] [Abstract][Full Text] [Related]
7. Hepatic iron overload does not prevent a sustained virological response to interferon-alpha therapy: a long term follow-up study in hepatitis C-infected patients with beta thalassemia major.
Sievert W; Pianko S; Warner S; Bowden S; Simpson I; Bowden D; Locarnini S
Am J Gastroenterol; 2002 Apr; 97(4):982-7. PubMed ID: 12003436
[TBL] [Abstract][Full Text] [Related]
8. Clinical features of hepatocellular carcinoma that occur after sustained virological response to interferon for chronic hepatitis C.
Ikeda M; Fujiyama S; Tanaka M; Sata M; Ide T; Yatsuhashi H; Watanabe H
J Gastroenterol Hepatol; 2006 Jan; 21(1 Pt 1):122-8. PubMed ID: 16706823
[TBL] [Abstract][Full Text] [Related]
9. Thrombocytopenia associated with chronic liver disease.
Afdhal N; McHutchison J; Brown R; Jacobson I; Manns M; Poordad F; Weksler B; Esteban R
J Hepatol; 2008 Jun; 48(6):1000-7. PubMed ID: 18433919
[TBL] [Abstract][Full Text] [Related]
10. [Natural interferon alpha (Le-IFNalpha) treatment in patients with thrombocytopenia during chronic HCV infection--our observations].
Krzowska-Firych J; Przybyła A; Modrzewska R
Przegl Epidemiol; 2009; 63(3):383-6. PubMed ID: 19899596
[TBL] [Abstract][Full Text] [Related]
11. Interferon therapy in hemodialysis patients with chronic hepatitis C virus infection induces a high rate of long-term sustained virological and biochemical response.
Espinosa M; Rodriguez M; Martin-Malo A; Alvarez de Lara MA; Gonzalez R; Lopez-Rubio F; de la Mata M; Aljama P
Clin Nephrol; 2001 Mar; 55(3):220-6. PubMed ID: 11316242
[TBL] [Abstract][Full Text] [Related]
12. Chronic hepatitis C virus infection in older adults.
Marcus EL; Tur-Kaspa R
Clin Infect Dis; 2005 Dec; 41(11):1606-12. PubMed ID: 16267733
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of thrombocytopenia among patients with chronic hepatitis C: a systematic review.
Louie KS; Micallef JM; Pimenta JM; Forssen UM
J Viral Hepat; 2011 Jan; 18(1):1-7. PubMed ID: 20796208
[TBL] [Abstract][Full Text] [Related]
14. [Thrombocytopenia in HCV infection. Natural interferon as an alternative therapy].
Krzowska-Firych J; Modrzewska R; Kiciak SG
Przegl Epidemiol; 2007; 61(4):771-6. PubMed ID: 18572510
[TBL] [Abstract][Full Text] [Related]
15. Chronic hepatitis C-associated thrombocytopenia: aetiology and management.
Fouad YM
Trop Gastroenterol; 2013; 34(2):58-67. PubMed ID: 24377151
[TBL] [Abstract][Full Text] [Related]
16. Genetic complexity of the hypervariable region 1 (HVR1) of hepatitis C virus (HCV): influence on the characteristics of the infection and responses to interferon alfa therapy in patients with chronic hepatitis C.
Pawlotsky JM; Pellerin M; Bouvier M; Roudot-Thoraval F; Germanidis G; Bastie A; Darthuy F; Rémiré J; Soussy CJ; Dhumeaux D
J Med Virol; 1998 Apr; 54(4):256-64. PubMed ID: 9557291
[TBL] [Abstract][Full Text] [Related]
17. A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan.
Yu ML; Lin SM; Chuang WL; Dai CY; Wang JH; Lu SN; Sheen IS; Chang WY; Lee CM; Liaw YF
Antivir Ther; 2006; 11(8):985-94. PubMed ID: 17302368
[TBL] [Abstract][Full Text] [Related]
18. [Efficacy of combination therapy with interferon-alpha and ribavirin for chronic hepatitis C in relation to liver fibrosis and serum aminotransferase activity].
Karpińska E; Wawrzynowicz-Syczewska M; Jurczyk K; Morańska I; Urbanowicz W; Boroń-Kaczmarska A
Wiad Lek; 2005; 58(11-12):616-21. PubMed ID: 16594470
[TBL] [Abstract][Full Text] [Related]
19. Long-term monitoring of platelet count, as a non-invasive marker of hepatic fibrosis progression and/or regression in patients with chronic hepatitis C after interferon therapy.
Taniguchi H; Iwasaki Y; Fujiwara A; Sakaguchi K; Moriya A; Yu PC; Takaki A; Fujioka S; Shimomura H; Shiratori Y
J Gastroenterol Hepatol; 2006 Jan; 21(1 Pt 2):281-7. PubMed ID: 16460487
[TBL] [Abstract][Full Text] [Related]
20. Sustained virological response to interferon reduces cirrhosis in chronic hepatitis C: a 1,386-patient study from Taiwan.
Huang JF; Yu ML; Lee CM; Dai CY; Hou NJ; Hsieh MY; Wang JH; Lu SN; Sheen IS; Lin SM; Chuang WL; Liaw YF
Aliment Pharmacol Ther; 2007 May; 25(9):1029-37. PubMed ID: 17439503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
